EDSS

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The article alleges that one of the Companys autonomously driven trucks left its lane of travel without warning before striking a cement barricade.
  • The article also reveals that the Federal Motor Carrier Safety Administration has launched a safety compliance investigation.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, August 5, 2022 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022 - 10:18pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Atara issued a press release on July 12, 2022, updating the market on its preliminary analysis phase 2 EMBOLD study for product candidate ATA188.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.

Retrieved on: 
Wednesday, July 27, 2022 - 3:49pm

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.

Key Points: 
  • New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .
  • Then, on February 28, 2022, Atara issued a press release attached to their Form 8-K, providing an update on ATA188.

Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data

Retrieved on: 
Thursday, July 14, 2022 - 1:00pm

SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology. Demyelination is a hallmark symptom of MS that occurs when the immune system attacks nerve fibers, causing lesions in the brain and spine. 

Key Points: 
  • The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology.
  • Clinical scores currently used as endpoints and screeners in trials are imprecise and do not always correlate with lesion activity.
  • "Rune's AI platform enables us to take raw brain data and convert it into actionable biomarkers of myelination."
  • Rune Labs' first-in-class precision neurology software platform uses machine learning to capture and analyze electrophysiological brain data to uncover previously overlooked markers of disease.

Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Retrieved on: 
Tuesday, July 12, 2022 - 9:30pm

The IA was planned to occur before enrolling patient 80 to enable an increased sample size if needed.

Key Points: 
  • The IA was planned to occur before enrolling patient 80 to enable an increased sample size if needed.
  • The IDSMC believes the six-month interim endpoint may be an inaccurate measure of the potential of this intervention in this condition.
  • The IDSMC recommended continuing the study without sample size adjustment until the final analysis of the primary endpoint of confirmed EDSS improvement at 12 months.
  • Following the EMBOLD IA, we are proceeding with the IDSMCs recommendation that the study continue to completion without sample size adjustment, said Jakob Dupont, M.D., Head of Global Research & Development at Atara.

OM1 LAUNCHES A NEW ESTIMATION MODEL FOR THE EXPANDED DISABILITY STATUS SCORE (EDSS) FOR MULTIPLE SCLEROSIS PATIENTS

Retrieved on: 
Thursday, June 23, 2022 - 9:05pm

BOSTON, June 23, 2022 /PRNewswire/ -- OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by Sage Publications.

Key Points: 
  • Scores can help determine the course of illness, need for different levels of care, and help guide treatment decisions.
  • Nearly 1 million Americans suffer from MS. With no cure, delay in diagnosis and treatment can result in permanent disability.
  • Once diagnosed, clinicians use the Expanded Disability Status Score (EDSS) to evaluate and measure disability levels in MS patients.
  • For this study, OM1 extrapolated data from the OM1 PremiOM MS Dataset to amplify and expand existing clinician rated EDSS scores.

REDEFINING THE LUXURY CROSSOVER THAT LAUNCHED A SEGMENT: THE ALL-NEW 2023 LEXUS RX

Retrieved on: 
Wednesday, June 1, 2022 - 1:00am

Today, Lexus redefined what the RX means to guests with the global reveal of the all-new RX at the Lexus New Product Showcase.

Key Points: 
  • Today, Lexus redefined what the RX means to guests with the global reveal of the all-new RX at the Lexus New Product Showcase.
  • The 2023 Lexus RX, the fifth generation for the Lexus core model, is completely redesigned from the wheels to the roof rails, featuring a new global platform, two all-new grades, available Digital Key, Lexus Safety System+ 3.0 and Lexus Interface Multimedia System.
  • The 2023 RX builds on the foundation of the iconic Lexus spindle design and evolves into a new, cohesive spindle body design.
  • The 2023 RX will be offered in six grades: Standard, Premium, RX-first Premium+, Luxury, F SPORT Handling and RX-first F SPORT Performance.

Mapi Pharma to Present Late Breaking Poster Presentation on GA Depot for Treating Primary Progressive Forms of Multiple Sclerosis at CMSC 2022 Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022 - 2:00pm

GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).

Key Points: 
  • GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).
  • GA Depot consists of extended-release microspheres containing GA, administered intramuscularly (IM) once every 28 days.
  • Mapi Pharma partnered with Viatris (NASDAQ: VTRS) for GA Depot in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.